Education

MBA Seattle University, 2012
PhD Epidemiology, University of Washington, 1997
MS Epidemiology, University of Washington, 1995
BSN University of Washington, 1991

Contact

206-285-3500
darthur@uw.edu

Bio

Dr. David Shoultz is the Chief Operating Officer and Co-Founder of Monod Bio, Inc. Monod Bio is a biotechnology company focused on creating new clinical diagnostics and laboratory tools based on its de novo protein design platform for biosensors.  The Company is a spin-out from the lab of Dr. David Baker at the University of Washington Institute for Protein Design (IPD).

Prior to launching Monod Bio with his co-founders Drs. Daniel Silva Manzano and Alfredo Quijano Rubio, David held multiple positions of increasing responsibility at biotech, pharmaceutical, and life sciences companies.  In addition, he held significant leadership positions in global health product development at the Bill & Melinda Gates Foundation and PATH.  At PATH, David was the Global Program Leader for the Drug Development Program.

David received his bachelor’s degree, M.S., and Ph.D. from the University of Washington in Seattle. His MBA is from the Albers School of Business & Economics at Seattle University, where he is a faculty member in the Executive MBA Program. He has been on the Affiliate Faculty at the University of Washington in the departments of Epidemiology and Global Health for more than twenty (20) years, has advised students, given guest lectures, and designed and taught courses on global health.  In addition, he was a member of the faculty at the Seattle University School of Business & Economics for many years; there he advised students and taught courses on strategy, operations, and global health.

David's expertise includes the development of diagnostics, drugs, and vaccines.  He has been very successful raising venture capital for various enterprises and serves as an advisor to private equity firms. His work has convinced him of the critical role that the private sector plays in public health, poverty alleviation, and innovation. He has a special interest in infectious diseases.